06:12

Untangling ASCO 2025 Data in Oncology: Episode 1

03:41

Clinical Judgment: Optimal Care vs Selection Bias in Oncology: Episode 3

03:47

Clinical Judgment: Optimal Care vs Selection Bias in Oncology: Episode 2

01:30

Dr Scarfò on Updated Safety Data With BGB-16673 in Relapsed/Refractory CLL/SLL

01:36

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma

01:23

Dr Curtis on Cyclophosphamide GVHD Prophylaxis in Matched Donor Transplant

01:57

Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL

01:58

Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AML

02:11

Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS

01:23

Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma

01:50

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

03:37

Clinical Judgment: Optimal Care vs Selection Bias in Oncology: Episode 1

06:40

The Current Financial Reality of Cancer Care in the US: Episode 3

04:27

The Current Financial Reality of Cancer Care in the US: Episode 2

03:31

The Current Financial Reality of Cancer Care in the US: Episode 1

04:22

The Dual Nature of Cancer Treatment: Episode 3

03:32

The Dual Nature of Cancer Treatment: Episode 2

04:17

The Dual Nature of Cancer Treatment: Episode 1

07:52

Ethical Considerations in Cancer Research: Episode 3

07:57

Ethical Considerations in Cancer Research: Episode 2

01:33

Dr He on the FDA Approval of Nivolumab Plus Ipilimumab for Unresectable/Metastatic HCC

06:28

Ethical Considerations in Cancer Research: Episode 1

05:22

Hope's Role in Cancer Management: Episode 3

05:36

Hope's Role in Cancer Management: Episode 2

03:58

Hope's Role in Cancer Management: Episode 1

04:44

Clinical Trials in Oncology: Episode 3

05:24

Clinical Trials in Oncology: Episode 2

02:12

Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC

04:31

Clinical Trials in Oncology: Episode 1

06:06

Prognostic vs Predictive Factors in Oncology: Episode 3

01:29

Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases

01:56

Dr Ahluwalia on the Evolution of Precision Medicine in Oncology

04:40

Prognostic vs Predictive Factors in Oncology: Episode 2

05:07

Prognostic vs Predictive Factors in Oncology: Episode 1

03:02

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

01:30

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

02:29

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

01:58

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

01:37

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

01:40

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

04:21

A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 3

05:35

A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 2

02:58

Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed Myeloma

02:35

Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma

03:47

Dr Piotrowska on Treatment Sequencing Decisions in HER2-Mutated NSCLC

02:28

Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC

03:08

Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm

01:31

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

03:43

A Pragmatist's View on Biomarker-Driven Decisions in Oncology: Episode 1

04:34

Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC

01:22

Dr Ghia on a Pooled Analysis of OS Outcomes With Ibrutinib Plus Venetoclax in CLL

03:28

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC

03:49

Molecularly Targeted Therapies in Oncology: Episode 4

32:59

Dr. DeVita Discusses "The Death of Cancer"

03:13

Molecularly Targeted Therapies in Oncology: Episode 3

03:09

Molecularly Targeted Therapies in Oncology: Episode 2

03:40

Molecularly Targeted Therapies in Oncology: Episode 1

03:13

Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

01:08

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

01:05

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer